Thelma 9 weeks after Stem Cell Therapy – Video
By raymumme
Thelma 9 weeks after Stem Cell Therapy
I created this video with the YouTube Video Editor (www.youtube.com
By: krazykp12
Uncategorized
Comments Off on Thelma 9 weeks after Stem Cell Therapy – Video |
January 25th, 2013
Thelma 8 weeks after Stem Cell Therapy – Video
By Dr. Matthew Watson
Thelma 8 weeks after Stem Cell Therapy
By: krazykp12
See the article here:
Thelma 8 weeks after Stem Cell Therapy - Video
Uncategorized
Comments Off on Thelma 8 weeks after Stem Cell Therapy – Video |
January 24th, 2013
Head Injury Improves After Stem Cell Therapy – Video
By JoanneRUSSELL25
Head Injury Improves After Stem Cell Therapy
Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com
By: neurogenbsi
Read the original post:
Head Injury Improves After Stem Cell Therapy - Video
Uncategorized
Comments Off on Head Injury Improves After Stem Cell Therapy – Video |
January 21st, 2013
Moderate Mental Retardation with Behavioral Issues Improves with Stem Cell Therapy – Video
By Sykes24Tracey
Moderate Mental Retardation with Behavioral Issues Improves with Stem Cell Therapy
Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com
By: neurogenbsi
See more here:
Moderate Mental Retardation with Behavioral Issues Improves with Stem Cell Therapy - Video
Uncategorized
Comments Off on Moderate Mental Retardation with Behavioral Issues Improves with Stem Cell Therapy – Video |
January 20th, 2013
Things to know about the real fountain of youth
By Dr. Matthew Watson
Fountain of youth is referred to a spring. If a person drinks the water of it, he or she can easily restore the youth again in themselves. In his writing Herodotus has also mentioned about this concept. This has become a kind of legend and many a famous author like Homer or Shakespeare have also discussed about in the literature. Now the biggest question is that whether there is really any kind of such fountain on this earth or not.
How the search goes on:
The search of such a fountain goes generation after generation because men have always wanted more youth. With the progress of science men have made many an incredible thing successful. The use of stem cells and many other related inventions have made huge change in human life. Men and women are getting longer and fitter life. More researches on cells are going on and scientists are working very hard to invent various things by the help of which we can keep our youth for longer time.
What the concept is:
Though the whole thing comes from a myth but the main aspect of this thought is to get back the life again. Man has always searched for immortality. According to scientists, now they have found out a way to continue your youth for longer time. Actually our body can have the charm of youth because of cell division. Normally a cell can divide for fifty times and then gradually it stops and the characteristics of old age begin to come in the body. Now the scientists have succeeded to produce such a cell which can divide it over 90 times and still it will not get slow down. Scientists have used an enzyme with the chromosomes the name of which is Telomerase. Telomere shortening is the actual reason of gradually getting old. Now this enzyme will stop the normal shortening process of telomere and thus it can help you to keep your youth in yourself for longer time.
Its drawback:
This enzyme is undoubtedly one of the most incredible inventions at the moment but it may have some drawbacks. According to some of the scientists this shortening process of telomere is a natural process. Now this natural process can eventually ward off cancer. Now by adding this enzyme this natural process of body defense will be destroyed. Some of the scientists are worried of the consequences of that. More experiments are going on and after the successful completion of them the scientists will be able to state the result of this new invention.
Searching for longer life:
Most of the people on this earth like to have a longer life especially a longer youth in which he will have ample energy to enjoy all the entertaining aspects of life. The concept of fountain of youth has been traditionally carried forward generation after generation because of this continuous wish of longer life of human being.
The myth of finding a fountain where the water can be found which can bring back youth may not be found physically. However, progress of science can assure a longer youth for human. In recent future man is going to live a longer enjoyable life.
About The Author: Claudia is a writer/ blogger. She loves writing, travelling and reading books. She contributes to Caribbean Cruise Line Scam
Source:
http://www.biotechblog.org/entry/real-fountain-youth/
Uncategorized
Comments Off on Things to know about the real fountain of youth |
January 20th, 2013
Animal Welfare Institute Requests Action from Federal Agencies on Santa Cruz … – Bay Area Indymedia
By Dr. Matthew Watson
Animal Welfare Institute Requests Action from Federal Agencies on Santa Cruz ... Bay Area Indymedia On behalf of the Animal Welfare Institute (AWI), I am writing to respectfully request that you take urgent action to immediately revoke the dealer license of Santa Cruz Biotechnology, Inc. (SCBT), license #93-B-0192. SCBT has been cited by USDA for ... Lawsuit Claims Animal Cruelty By Santa Cruz Biotech FirmCBS Local Animal rights organization files suit against Santa Cruz BiotechInside Bay Area |
Uncategorized
Comments Off on Animal Welfare Institute Requests Action from Federal Agencies on Santa Cruz … – Bay Area Indymedia |
January 20th, 2013
Federal Investigations Reveal Severe Neglect of Animals at Santa Cruz … – Bay Area Indymedia
By Dr. Matthew Watson
 Bay Area Indymedia | Federal Investigations Reveal Severe Neglect of Animals at Santa Cruz ... Bay Area Indymedia According to inspection reports, Santa Cruz Biotechnology houses approximately 10,000 goats and 6,000 rabbits as well as horses and cattle not regulated by the USDA. (Anthro/iStockphoto.com) Thursday, January 17, 2013. Contacts: Michael Budkie, SAEN ... |
Uncategorized
Comments Off on Federal Investigations Reveal Severe Neglect of Animals at Santa Cruz … – Bay Area Indymedia |
January 20th, 2013
Genetech Biotechnology Corp. (OTC:GNBT) Recovers Lost Ground – HotStocked
By Dr. Matthew Watson
HotStocked | Genetech Biotechnology Corp. (OTC:GNBT) Recovers Lost Ground HotStocked 2 Comments. Watch the video to learn about the probability of Generex Biotechnology Corp. (GNBT) Chart Signal as of Jan 19 2013. Get Adobe Flash player. This free program will calculate the probabilities of Generex Biotechnology Corp. (GNBT) stock ... Before You Start Your Long Weekend, Check Out These Three Budding Ideas ...SmallCap Network |
Uncategorized
Comments Off on Genetech Biotechnology Corp. (OTC:GNBT) Recovers Lost Ground – HotStocked |
January 20th, 2013
StemCells, Inc., Still Looking for $40 Million from California Stem Cell Agency
By Dr. Matthew Watson
million it was awarded by the California stem cell agency.
eminent Stanford researcher Irv Weissman, received an award of $20
million last July and then again in September. Nearly five months
later, however, the stem cell agency has yet to cut a check for the
company, a spokesman for the agency told the California Stem Cell
Report in response to a query.
matching funds that the company promised the agency. The stem cell
agency has yet to be satisfied that StemCells, Inc., can actually
produce the match, although the spokesman did not offer details.
unusual in a number of ways. It was the first time that former CIRM
Chairman Robert Klein lobbied the CIRM governing board on behalf of a
company(see here and here). It was the first time that the governing
board approved an application that had been rejected twice by grant
reviewers. It was the first time that the board said explicitly in a
public session that it wanted proof of the matching funds as a
condition of the award.
to a company received a careful and critical scrutiny from a major
California newspaper. Michael Hiltzik, a Pulitzer Prize-winning
business columnist and author, wrote in October in the Los Angeles
Times that the award was “redolent of cronyism.” He referred
particularly to longstanding ties between Klein and Weissman.
Inc., grant in September was 7-5, which amounted to 12 out of 29
members of the board.
Institute of Medicine (IOM) recommended that the agency tighten its
conflict of interest standards to avoid such perceptions as have been
generated by the StemCells, Inc., awards. The IOM said,
“(C)ompeting personal and
professional interests compromise the perceived independence of
the (governing board), introduce potential bias into the board’s decision
making, and threaten to undermine confidence in the board.”
Concerns about conflicts of interest have long been of concern to observers of the stem cell agency for years. Indeed, the prestigious journal Nature in 2008 warned of "cronyism" at the $3 billion research enterprise.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/5BdZ8FguJp8/stemcells-inc-still-looking-for-40.html
Stem Cell Therapy
Comments Off on StemCells, Inc., Still Looking for $40 Million from California Stem Cell Agency |
January 20th, 2013
Stem Cell Agency Chair Pressing for Consensus on IOM Recommendations
By Dr. Matthew Watson
The chairman of the $3 billion
California stem cell agency, Jonathan Thomas, yesterday outlined how
he intends to proceed next week when the agency's governing board
considers the far-reaching recommendations of a blue-ribbon Institute
of Medicine panel.
said,
“While some of the IOM’s
recommendations are administrative in nature and can be implemented,
others are much more complex and would require changes in (governing)
board policy or legislative changes.”
 |
| Jonathan Thomas, chairman of CIRM governing board at far right. Art Torres (center), co-vice chair and former state Democratic party chairman, who would play key role in dealing with lawmakers. Robert Klein is at the left in this 2011 meeting, Klein's last as chairman of the agency and the one in which Thomas was elected chairman. |
“My goal is to strive to reach
consensus on a course of action on the 23rd. However, if the board
isn’t able to choose a course of action at this time we will
continue the conversation and bring it up at future board meetings
until we reach agreement.”
mention the possibility of having to ask the people of California to
amend the state constitution, which would require a statewide election. Opponents to change at the agency have
used that possibility to discourage action. (See here and here.) An
election would be costly, politically difficult and could open the
door to additional unwelcome changes at the eight-year-old research
enterprise.
the 29 board members – instead of a simple majority – could be a
stumbling block as the board becomes snarled internally, perhaps for
months or more. The board normally meets only about once a month and
has a full slate of regular business on those occasions. The agency
will run out of money for new grants in less than four years, and
action on the IOM recommendations seems a necessary prelude to
winning continued financial support.
period of time, making the sort of changes the IOM recommends would
require legislative action, which probably would take a minimum of a
year. Timing is important as well. The current leaders in the state
Senate and Assembly will be termed out in 2014. Starting all over
with novice leadership, changes in key committee chairmanships and so
forth would make the task even more difficult. Then there is the need
to address strategies for continued financial support. Should the
agency seek a new statewide bond measure (the current funding
mechanism)? If so campaign committees need to be formed, electoral
strategies planned and tested and tens of millions of dollars raised
for campaign expenses. If private funds instead are to be raised to
the tune of hundreds of millions of dollars(the agency spends about
$300 million a year), such an effort would also require considerable time.
To keep the funding pipeline full, all of this should be completed
well before the money runs out in 2017.
the IOM proposals would be an unfortunate beginning should CIRM
directors actually want to continue the existence of the
organization.
final note.
“It’s likely the debate will be
passionate – everyone involved in this work cares deeply about it –
and there will undoubtedly be disagreements, but ultimately we all
share the same goal, a desire to make sure that whatever we decide
helps make the stem cell agency even stronger and more effective, and
is in the best interests of the people of California.”
Source:Stem Cell Therapy
Comments Off on Stem Cell Agency Chair Pressing for Consensus on IOM Recommendations |
January 20th, 2013
UC Davis Stem Cell Researcher: ‘Ivory Tower’ IOM Recommendations Harmful to California Stem Cell Agency
By Dr. Matthew Watson
The $3 billion California stem cell
agency has funded in the neighborhood of 500 to 600 scientists and
institutions, reviving and starting careers and stimulating
construction of $1 billion in new research labs around the state.
know, has come forward to comment publicly on the sweeping recommendations by Institute of Medicine for changes at the agency.
Until today, that is.
may be the only stem cell scientist in the United States with a stem
cell blog, weighed in with his thoughts today, which do not align
with those of the blue-ribbon IOM panel.
actually make CIRM less effective and less responsive to patients and
California citizens.”
will come before stem cell agency governing board next week “...seems more like an ivory tower
intellectual exercise than an operative, realistic guide to a dynamic
agency that must operate in the real world.”
which came under fire from the IOM for conflicts of interest.
Institutions linked to board members have received about 90 percent
of the $1.7 billion that the board has awarded, according to compilations by the California Stem Cell Report. The IOM said,
“Far too many board members
represent organizations that receive CIRM funding or benefit from
that funding. These competing personal and professional
interests compromise the perceived independence of the ICOC,
introduce potential bias into the board’s decision making, and
threaten to undermine confidence in the board."
“(The) IOM itself admits there is no
evidence that any conflicts of interest have ever guided (the agency's governing board) decisions. Not one example.”
“Interestingly, highlighting the
extremely sensitive nature of this issue, while I’ve been talking
with many bigwigs about this, at this point no one is wiling to go on
the record with an opinion about it except one courageous soul, Don
Reed (see
his piece here).”
described as the gold standard. And it has a rareified membership
that many scientists seek to join. So few are ready to give the
organization a smack on the nose. Likewise, California researchers
are loath to publicly criticize the stem cell agency because it
holds the strings to the purse that finances their careers.
be asking themselves a bottom-line question. Do they want to see the
stem cell agency continue for another 10 to 20 years? Under the best
of circumstances, that may be unlikely given the other pressing needs
that the state faces. But if CIRM directors do not forthrightly
address the recommendations of the IOM panel, the fate of the stem
cell agency is exceedingly uncertain.
Source:Stem Cell Therapy
Comments Off on UC Davis Stem Cell Researcher: ‘Ivory Tower’ IOM Recommendations Harmful to California Stem Cell Agency |
January 20th, 2013
Patient Advocate Says IOM Recommendations Would ‘Destroy’ California Stem Cell Agency
By Dr. Matthew Watson
California's “beloved,” $3 billion
stem cell research program should not be altered despite
recommendations from the most prestigious scientific organization of
its kind. So says longtime patient advocate Don Reed of Fremont, Ca.
Institute of Medicine (IOM) are a “threat” that would “destroy” an
agency that “is like nothing else on earth.” Reed is urging other
patient advocates to turn out at next week's critical meeting of the stem cell agency's board and lobby against alterations in how it does
business.
 |
| Reed and CIRM's Amy Adams World Stem Cell Summit photo |
nationally and in California and has been a regular at the stem cell
agency's public meetings since 2004. He is also vice president of
Americans for Cures, a private stem cell lobbying group created by
Robert Klein when he was chairman of the stem cell agency, formally known as the California Institute for Regenerative
Medicine(CIRM).
report on his blog with duplicate publication on the Huffington Post.
Yesterday, he said IOM “defies” the voters' will when they
created the stem cell agency in 2004. On Dec. 19, he said the
$700,000, 17-month study was “staggeringly misguided.” He wrote,
“If its recommendations were enacted,
they would silence stem cell patient advocate involvement, eliminate
public debate on funding proposals, and delegate the real decisions
to secret proceedings by an out-of-state-controlled board.”
“fantastic” and wrote,
“So why mess with it, in such a
brutal and insulting manner?”
early days of the stem cell agency and respects him. But in this
case he has many of his facts wrong. To mention just a few key
points: Patient advocates would not be silenced; their role would be
changed. Public comment would not be eliminated. Scientists could
still appeal negative decisions by reviewers to the full board if
they so choose, although the “extraordinary petition” process
would be eliminated. The voters' will would not be defied; they provided for a mechanism for making changes in the stem cell program.
publicly on the IOM report, some of Reed's comments reflect Klein's
past positions against altering the agency. Klein, an attorney and
real estate investment banker, might well be considered the father of
the agency. He directed the writing of the 10,000-word measure, Prop. 71, that created the program and wrote much of ballot initiative himself. The initiative contained a detailed description of the
qualifications for the chairman, which fit only one person in
California. It was no surprise when he won the post.
in the board on earlier proposals for changes that he disliked and that the IOM report now echoes.
advocate for commissioning the IOM report which he expected
to serve as the basis for continued funding of the agency. It will
run out of cash for new grants in 2017.
said the IOM report would constitute a “gold standard” that would
generate increased enthusiasm for the research.
“(We will) never convince the people
that are adamant against us. But for the public and for the
constituent groups that are reasoned and prepared to look at
evidence, this is a very important validation that they can look to
to separate out what is a false claim from real performance.”
study was Bradley Fikes of the San Diego U-T, the dominant daily
newspaper in that area.
plans to file his own story within the next few days.
clicking on the word “comment” below or with the stem cell agency
at info@cirm.ca.gov. Anonymous
comments are permitted on this blog.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/wX7BEi46lc8/patient-advocate-says-iom.html
Stem Cell Therapy
Comments Off on Patient Advocate Says IOM Recommendations Would ‘Destroy’ California Stem Cell Agency |
January 20th, 2013
Live Audiocast Available for Next Week’s CIRM-IOM Meetings
By Dr. Matthew Watson
provide a live audiocast of next week's critical discussions of
action on the sweeping recommendations proposed for the agency by the
Institute of Medicine.
telephonic arrangement can be found on the agendas for Wednesday and
Thursday. Also expected to be posted soon on the Wednesday agenda are
recommendations by CIRM Chairman J.T. Thomas.
opportunity to listen and no opportunity to provide testimony. If you
are interesting in making suggestions or comments ahead of the
meeting, email them to info@cirm.ca.gov. The public can also testify at the board meeting.
Claremont Hotel in the Berkeley hills across the bay from CIRM's San
Francisco headquarters.
Source:Stem Cell Therapy
Comments Off on Live Audiocast Available for Next Week’s CIRM-IOM Meetings |
January 20th, 2013
California Stem Cell Face-Off: CIRM Directors Wrestle with Tough IOM Recommendations
By Dr. Matthew Watson
Two days next week at the posh
Claremont Hotel in the Berkeley hills could settle the fate of
California's $3 billion stem cell agency.
board of the state research effort will begin a critical, two-day
public session. On the table will be the $700,000, blue-ribbon
report from the prestigious Institute of Medicine (IOM). The study
recommends sweeping changes in the structure and operations of the
California Institute of Regenerative Medicine (CIRM), as the stem
cell agency is formally known.
challenges for the agency. But the recommendations are freighted with
even more significance. Below the surface lies the hard fact of
CIRM's dwindling resources and possible demise. In less than four
years – without either renewed public support or private
contributions – the research effort will begin a shriveling,
downward spiral.
 |
| Claremont Hotel |
The IOM report places a special burden
on the agency governing board. The board paid the IOM to evaluate its
performance. In 2010, then CIRM Chairman Robert Klein trumpeted the
value of an IOM study, saying it would serve as a springboard for a
new, multibillion-dollar state bond measure for the agency(see here and here). Given the
state's difficult financial condition – not to mention the position
of potential private sector investors – winning approval of that
kind of investment will be more than difficult.
directors choose to ignore the major IOM recommendations, they will
hand opponents a devastating weapon, one that could be used to convince voters to reject
any proposal for continued funding. The board
would also give private investors more major reasons to say no to
CIRM pitches for cash.
board has rejected similar proposals for changes in the past. When
the IOM presented the study to the board just last month, the
reception was not much different. Several board members bristled. One
influential board member, Sherry Lansing, chair of the University of
California board of regents, said the directors' “hands are tied”
because some of the recommendations might require a vote of the people. Her comments echoed similar statements from Klein in 2009,
when he said board members would violate their oath of office if they
supported recommendations for changes that he opposed.
however, was relatively brief and less than definitive. Klein has
been off the board since June 2011, replaced by Los Angeles bond
financier Jonathan Thomas, who is regarded as a welcome change by a
number of board members.
within the agency itself. Conflict of interest rules would be
tightened. In some ways, the board would lose power, which would be
shifted to the president. The board would no longer vote on
individual applications – only a slate recommended by reviewers.
Applicants for CIRM awards would be directly affected, being barred
from making the sort of direct and public appeals that clogged the
CIRM board meetings last year. And that would be just the beginning.
to make his recommendations for action on the report, although they
have not yet been posted on the CIRM web site. Under what might be considered “normal” leadership, Thomas would be testing sentiment
among board members via personal conversations and phone calls.
However, in California that would be illegal – a violation of open
meeting laws that bar what are called “serial meetings” at nearly
all public agencies.
majority vote for anything significant among 29 strong-minded
individuals is not simple. But it is even more difficult when facing
a board that has a tradition of consensus management and
oversight.
interesting. The nearly 100-year-old, iconic Claremont hotel has a
troubled financial history. It was up for sale for $80 million last
spring but there were no takers. In the early 20th century, the
property on which it is located was lost and won in a checkers game
in Oakland, or so the story goes.
California stem cell agency. Moves next week by directors could
easily determine whether CIRM becomes nothing more than an
interesting scientific footnote or establishes a path that will lead
it to long-lasting leadership in regenerative medicine.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/SS09uwQmVDQ/california-stem-cell-face-off-cirm.html
Stem Cell Therapy
Comments Off on California Stem Cell Face-Off: CIRM Directors Wrestle with Tough IOM Recommendations |
January 20th, 2013
NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into a Cell Therapy Manufacturing Services Agreement With …
By Dr. Matthew Watson
ALLENDALE, N.J. and OXFORD, United Kingdom, Jan. 16, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced today a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286).
PCT's services will include the transfer and qualification of Adaptimmune's manufacturing process for its NYESO-1c259-T cell therapy product candidate at PCT's facility in Allendale, New Jersey and subsequent manufacturing of the product for Adaptimmune's clinical trials.
Adaptimmune develops products containing unique engineered T cell receptors for the treatment of cancer and infectious diseases. The company has a research base in Oxford, UK and a clinical base in Philadelphia, Pennsylvania.
In December, at the American Society of Hematology conference, Adaptimmune announced encouraging preliminary results from its expanded multiple myeloma trial. Related trials in melanoma and sarcoma are also recruiting patients.
PCT is an internationally recognized contract development and manufacturing organization with facilities in Allendale, New Jersey and Mountain View, California. The company has expertise in GMP manufacture for cell therapies, including dendritic cells, stem cells and T cells. Notably, PCT provided manufacturing for the pivotal studies for Dendreon's Provenge(R), the first cell therapy approved for cancer treatment.
"With our sights set on future pivotal trials for our T cell therapy products, we have invested significant effort towards establishing capabilities within Adaptimmune that support expansion of our clinical platform in terms of both scale and compliance with FDA requirements beyond phase I/II. Our relationship with PCT is an important component," said James Noble, Chief Executive Officer of Adaptimmune. "PCT's impressive level of experience in the burgeoning field of cell therapy, combined with their flexible capacity and professionalism, are among the reasons we selected them for this critical role for our T cell product."
"We are excited to enter into this agreement with Adaptimmune, an innovator for T cell therapy to treat cancers," said Robert A. Preti, PhD, President and Chief Scientific Officer of PCT. "Given our extensive experience with technology transfer, process qualification and GMP manufacturing, we feel PCT will be an asset to Adaptimmune as it develops its product for the U.S. commercial market."
Dr. Robin L. Smith, NeoStem's Chairman and Chief Executive Officer, stated that, "PCT's expertise is recognized globally as demonstrated by the services agreement executed with Adaptimmune. As PCT continues to expand its GMP manufacturing capabilities and focus to support the development of an increasingly wide range of cell therapies under development, it remains focused on providing outstanding client services."
About Adaptimmune
Adaptimmune focuses on the use of T cell therapy to treat cancer and infectious disease. It aims to use the body's own machinery -- the T cell -- to target and destroy cancerous or infected cells.
Uncategorized
Comments Off on NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into a Cell Therapy Manufacturing Services Agreement With … |
January 16th, 2013
Stem Cell Therapy Guidelines Readied
By NEVAGiles23
MANILA, Philippines --- The Department of Health (DOH) is preparing guidelines for the use of stem cell therapy in the treatment of diseases in the Philippines.
This was announced by DOH Secretary Enrique T. Ona yesterday in a convention on stem cell therapy at the Manila Hotel.
Ona said a bio-ethics advisory board will develop the guidelines which will include ethical standards in the application of stem cell therapy to treat diseases such as malignancies, blood disorders and metabolic disorders, among others.
"The institutional board will review and approve Stem Cell therapies based on guidelines by the advisory board," Ona said.
He added that the board will also include ethical and legal issues surrounding stem cell therapy.
Last week, the Philippine Medical Association (PMA) and the Philippine Society for Stem Cell Medicine (PSSCM) issued a joint statement that warned against the dangers of receiving stem cell transplants that came from another source other than the patient's body.
"If the stem cell that you received is not from your own body, it could lead to fatal complications," Philippine Society for Stem Cell Medicine (PSSCM) and the PMA said.
The doctors warned that complications arising from stem cell transplants include graft-versus-host disease, stem cell (graft) failure, organ injury, infections, cataracts, infertility, new cancers, and even death.
Ona said a public hearing will be held on January 18 regarding the preliminary draft of the guidelines.
He said the guidelines will ensure the minimum quality of service and application in the use of stem cells in health settings.
See the original post:
Stem Cell Therapy Guidelines Readied
Uncategorized
Comments Off on Stem Cell Therapy Guidelines Readied |
January 16th, 2013
SanBio Announces Enrollment Of The Second Cohort Of Patients In Its Clinical Trial Of Stem Cell Therapy For Chronic …
By Dr. Matthew Watson
MOUNTAIN VIEW, Calif., Jan. 14, 2013 /PRNewswire/ --SanBio Inc. today announced the successful enrollment of the second dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 12 patients, of a planned total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University, the University of Pittsburgh and Northwestern University. No safety concerns have been attributed to the cell therapy product. For details regarding this clinical trial, please refer to http://www.strokeclinicaltrial.org.
SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of chronic stroke. "The successful completion of the first two dose cohorts of this pioneering clinical trial is a clear indication of the dedication and professionalism of the entire team," said Keita Mori, SanBio CEO.
SB623 is being delivered to the damaged region of the brains of patients who have suffered an ischemic stroke. Product safety is the primary focus of the study but various measurements of efficacy are also being tested.
"We are pleased with the safety findings of the study thus far," said Dr. Ernest Yankee, SanBio's Executive Vice President of Development. "We anticipate completing the enrollment of the third and final dose cohort early in the year and reporting the results shortly thereafter."
About SB623: SB623 is a proprietary cell therapy product consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors. SB623 is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process.
About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.
For more information: http://www.san-bio.com
Read the rest here:
SanBio Announces Enrollment Of The Second Cohort Of Patients In Its Clinical Trial Of Stem Cell Therapy For Chronic ...
Uncategorized
Comments Off on SanBio Announces Enrollment Of The Second Cohort Of Patients In Its Clinical Trial Of Stem Cell Therapy For Chronic … |
January 14th, 2013
Swaminathan for biotechnology regulatory body – The Hindu
By Dr. Matthew Watson
 The Hindu | Swaminathan for biotechnology regulatory body The Hindu Noted agricultural scientist and Rajya Sabha member M.S. Swaminathan on Tuesday stressed the need for putting in place an autonomous biotechnology regulatory authority for ensuring bio-security of the country, with respect to the clearance of ... |
Uncategorized
Comments Off on Swaminathan for biotechnology regulatory body – The Hindu |
January 13th, 2013
Gene Therapies Will Cure Many a Disease (preview)
By Dr. Matthew Watson
The Science Of The Next 150 Years: 50 Years in the Future [More]
http://rss.sciam.com/click.phdo?i=72f945621480bfc5969f6a7a29254aaf
Uncategorized
Comments Off on Gene Therapies Will Cure Many a Disease (preview) |
January 13th, 2013
The Science of the Next 150 Years
By Dr. Matthew Watson
What scientific and technological milestones can we envision 50, 100 and 150 years hence?
http://rss.sciam.com/click.phdo?i=bb22bbe61dfa476fb230c7787f0d7954
Uncategorized
Comments Off on The Science of the Next 150 Years |
January 13th, 2013